franci63
Forumer storico
Direi di sì...
...forse anche 1,181/1,182...
...ma non so per quanto può resistere a certe "altezze"...
:vicini:
....fammi divertire almeno coi simboletti va.....notte mitico
El.En (ELN) El.En.: la bella addormentata con oltre 60 milioni di "dote"...
- Creatore Discussione Spotti
- Data di Inizio
:vicini:....fammi divertire almeno coi simboletti va.....notte miticoSpotti
.
Direi di sì...
...forse anche 1,181/1,182...
...ma non so per quanto può resistere a certe "altezze"...
P.S.
Guarda il lato positivo: fino a quando non sale riuscirai ad evitare di dilapidare di nuovo un patrimonio come hai fatto in passato!
È sufficiente richiamare i bei tempi andati perché tu faccia subito festa...
Spotti
.
Domani sera avremo qualcosa di cui parlare...
Cynosure To Host Third-Quarter 2015 Financial Results Conference Call On October 27 - MarketWatch
Cynosure To Host Third-Quarter 2015 Financial Results Conference Call On October 27 - MarketWatch
vincislato
Forumer attivo
Domani sera avremo qualcosa di cui parlare...
Cynosure To Host Third-Quarter 2015 Financial Results Conference Call On October 27 - MarketWatch
dati sembrano buoni:
Cynosure Announces Third-Quarter 2015 Results; Revenue of $78.4 Million, 10 Percent Increase... -- WESTFORD, Mass., Oct. 27, 2015 /PRNewswire/ --
non mi ricordo però quali erano le attese..
franci63
Forumer storico
TonyM
......SEMPRE AVANTI!
Ancora con questa fantomatica t.opa americana su El.En ?
Qui l'unico che ancora tratta la t.opa a dovere è TonyM..
Dopo essersi fatto avanti con quella ragazza ha iniziato a scrivere molto meno nel forum..
Ieri sera abbiamo parlato per due ore......
Ci sto lavorando, ci sto lavorando.....
AmonCM
Forumer attivo
Ieri sera abbiamo parlato per due ore......
Ci sto lavorando, ci sto lavorando.....
Bravo ragazzo!!!
Si lavora e si fatica
Per il pane per la f
Si lavora tutto l'anno
ma la f
non ce la danno
vincislato
Forumer attivo
questa sembra che sia passata inosservata (da questa parte dell'oceano perchè a WS ha spinto al rialzo il titolo il giorno successivo al boom per i risultati)...
Cynosure obtains medical device license from Health Canada to market MonaLisa Touch for treatment of GSM symptoms
Published on October 28, 2015 at 9:07 AM · No Comments
Cynosure, Inc. (NASDAQ: CYNO) today announced that it has received a medical device license issued by Health Canada to market MonaLisa Touch® for the treatment of symptoms related to Genitourinary Syndrome of Menopause (GSM), including vaginal dryness, vaginal burning, vaginal itching, pain, dysuria and dyspareunia. The condition affects approximately half of all postmenopausal women.
"Health Canada's authorization of MonaLisa Touch is an important regulatory milestone for Cynosure as we continue to expand the geographic reach of this innovative and efficacious aesthetic medical technology to new markets," said Cynosure CEO Michael Davin. "With its varied and sometimes debilitating symptoms, GSM can significantly affect quality of life. We are excited about the ability to offer the nearly 7 million mid-life and older women in Canada this potentially life-changing treatment, which we believe has the potential to rapidly become a first-line therapy for GSM."
Related Stories
NAMS panel provides recommendations to help women manage menopause-associated vasomotor symptoms
Research on investigational menopause drug wins first prize
Endocrine Society issues Clinical Practice Guideline on treatment of menopausal symptoms
MonaLisa Touch is a fractional carbon dioxide (CO2) laser specifically designed to help restore vaginal health in postmenopausal women as well as breast cancer survivors. The procedure is performed in an office environment without the need for anesthesia and with virtually no pain or side effects. MonaLisa Touch, which has successfully treated thousands of patients around the world, received marketing clearance from the U.S. Food and Drug Administration in September 2014.
GSM is a comprehensive term that includes symptomatic vulvovaginal atrophy as well as lower urinary tract symptoms related to low estrogen levels. Symptoms can be chronic and progressive and are unlikely to improve over time.
In addition to the treatment of GSM symptoms, Health Canada also authorized the marketing of MonaLisa Touch for incision, excision, ablation, vaporization and coagulation of body soft tissues in gynecology and genitourinary surgery.
Cynosure obtains medical device license from Health Canada to market MonaLisa Touch for treatment of GSM symptoms
Published on October 28, 2015 at 9:07 AM · No Comments
Cynosure, Inc. (NASDAQ: CYNO) today announced that it has received a medical device license issued by Health Canada to market MonaLisa Touch® for the treatment of symptoms related to Genitourinary Syndrome of Menopause (GSM), including vaginal dryness, vaginal burning, vaginal itching, pain, dysuria and dyspareunia. The condition affects approximately half of all postmenopausal women.
"Health Canada's authorization of MonaLisa Touch is an important regulatory milestone for Cynosure as we continue to expand the geographic reach of this innovative and efficacious aesthetic medical technology to new markets," said Cynosure CEO Michael Davin. "With its varied and sometimes debilitating symptoms, GSM can significantly affect quality of life. We are excited about the ability to offer the nearly 7 million mid-life and older women in Canada this potentially life-changing treatment, which we believe has the potential to rapidly become a first-line therapy for GSM."
Related Stories
NAMS panel provides recommendations to help women manage menopause-associated vasomotor symptoms
Research on investigational menopause drug wins first prize
Endocrine Society issues Clinical Practice Guideline on treatment of menopausal symptoms
MonaLisa Touch is a fractional carbon dioxide (CO2) laser specifically designed to help restore vaginal health in postmenopausal women as well as breast cancer survivors. The procedure is performed in an office environment without the need for anesthesia and with virtually no pain or side effects. MonaLisa Touch, which has successfully treated thousands of patients around the world, received marketing clearance from the U.S. Food and Drug Administration in September 2014.
GSM is a comprehensive term that includes symptomatic vulvovaginal atrophy as well as lower urinary tract symptoms related to low estrogen levels. Symptoms can be chronic and progressive and are unlikely to improve over time.
In addition to the treatment of GSM symptoms, Health Canada also authorized the marketing of MonaLisa Touch for incision, excision, ablation, vaporization and coagulation of body soft tissues in gynecology and genitourinary surgery.
Similar threads
